A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Exclusion Criteria

• •Participants with a history of exposure to varicella through contact with a varicella patient at home, school, or childcare facility within 4 weeks before Screening
• •Participants with a history of varicella infection and varicella vaccine, either licensed or investigational, and either standalone or any combination, such as MMRV
• •Participants with acute moderate or severe infection with or without fever at the time of dosing
• •Participants who have had any suspected allergy symptoms, such as systemic rash, during the 72 hours before each administration of investigational product